Gene therapy aimed at cutting opioid use for diabetic nerve pain – but trial never started
NCT ID NCT04087941
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a gene therapy called VM202 in people with painful diabetic neuropathy who were already taking opioid painkillers. The goal was to see if VM202 could help them safely reduce their opioid dose. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VM202 (a DNA plasmid gene therapy that produces hepatocyte growth factor)
What this could lead to
If successful, this could offer a way to reduce or replace opioid painkillers for people with painful diabetic neuropathy, potentially lowering addiction risk.
What could go wrong
The trial was withdrawn before enrolling anyone, so no results exist. Gene therapies like VM202 are still experimental, and safety or effectiveness in humans is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAINFUL DIABETIC NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Translational Pain Research, Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States